Abstract
AbstractAlzheimer's disease (AD) is a chronic and progressive neurodegenerative disorder with long preclinical and prodromal phases in older people. Molecular imaging is a promising approach for noninvasive in vivo identification and tracking pathophysiological changes. In particular, nuclear neuroimaging in AD has extended beyond traditional evaluation of brain perfusion and glucose metabolism, and has achieved substantial progress over the past 2 decades. To gain a comprehensive understanding of nuclear neuroimaging with different targets in the brain, this review provides an overview of the literature on the current status and recent progress of the development of radioligands for definitive and differential diagnosis of AD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
